肝细胞癌免疫检查点抑制剂联合治疗的挑战
本文综述了靶向抗PD-1/抗PD-L1的免疫检查点抑制剂(ICI)联合方案治疗肝细胞癌(HCC)的早期试验更新数据,讨论了抗血管生成多激酶抑制剂与特异性VEGF/VEGFR抑制剂的相对获益与机制,并探讨了免疫相关不良事件管理和ICI联合局部治疗的价值。
要点
- 抗PD-1/抗PD-L1是HCC联合方案 backbone,早期试验数据支持其提高客观缓解与生存。
- 抗血管生成多激酶抑制剂与特异性VEGF/VEGFR抑制剂在联合ICI中的相对获益和机制需区分。
- 免疫相关不良事件优化管理及ICI联合局部治疗是HCC联合免疫治疗的关键议题。
核心结论
- ICI联合方案是改善HCC患者客观缓解和生存的重要策略,但研究设计、候选方案选择、预测生物标志物及毒性管理仍存挑战。
研究设计与样本
- 综述类文章,汇总HCC联合免疫治疗早期试验的更新数据,并参考其他癌种免疫肿瘤试验的设计经验。
主要发现
- 晚期HCC中测试最广泛的联合方案为抗PD-1/抗PD-L1药物联合抗血管生成药物。
- 抗血管生成多激酶抑制剂与特异性VEGF/VEGFR抑制剂在联合ICI时的相对获益和抗肿瘤机制存在差异。
临床怎么用
- 临床选择HCC联合免疫方案时应参考早期试验数据,关注抗血管生成药物类型差异及免疫相关不良事件管理。
- ICI联合局部治疗在HCC中的价值需进一步评估,预测生物标志物有助于筛选获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at improving the objective response and survival of patients with hepatocellular carcinoma (HCC). Clinical trials of immuno-oncology regimens in other cancer types have shed light on issues of study design, including how to choose candidate regimens based on early-phase trial results, statistical considerations in trials with multiple primary endpoints, and the importance of predictive biomarkers. In this review, the updated data from early-phase trials of combination immunotherapy for HCC are summarised. Since the most extensively tested combination regimens for advanced HCC comprise anti-PD-1/anti-PD-L1 agents plus antiangiogenic agents, the relative benefit and antitumor mechanism of antiangiogenic multikinase inhibitors versus specific VEGF/VEGFR inhibitors are discussed. Other critical issues in the development of combination immunotherapy, including optimal management of immune-related adverse events and the value of ICI therapy in combination with locoregional treatment for HCC, are also explored.
引用
- Cheng AL, Hsu C, Chan SL, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020. PMID: 31954494. doi:10.1016/j.jhep.2019.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。